Title:
USE OF INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO RTK HYPERFUNCTION, ESPECIALLY CANCER
Document Type and Number:
WIPO Patent Application WO1999037299
Kind Code:
B1
Abstract:
The invention relates to the use of inhibitors for the treatment and/or prevention of diseases resulting from increased receptor tyrosine kinase activity, especially cancer. Use concerns particularly the inhibition or reduction of over-expression and/or altered activity of receptor tyrosine kinases (RKTs). Such changes in the activity of receptor tyrosine kinase may be triggered particularly by a mutation of the FGFR-4, which mutation is especially a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic for a hydrophilic amino acid. The invention further relates to the use of an inhibitor directed against FGFR-4 for the treatment and/or prevention of cancer. The invention also relates to a mutated FGFR-4 causing overexpression and/or altered activity in cells. The invention finally relates to a DNA and RNA sequence of a mutated FGFR-4 molecule, a pharmaceutical composition comprising the inhibitor described above, and a diagnostic and screening method.
More Like This:
Inventors:
ULLRICH AXEL (DE)
BANGE JOHANNES (DE)
KNYAZEV PJOTR (DE)
BANGE JOHANNES (DE)
KNYAZEV PJOTR (DE)
Application Number:
PCT/EP1999/000405
Publication Date:
October 28, 1999
Filing Date:
January 22, 1999
Export Citation:
Assignee:
MAX PLANCK GESELLSCHAFT (DE)
ULLRICH AXEL (DE)
BANGE JOHANNES (DE)
KNYAZEV PJOTR (DE)
ULLRICH AXEL (DE)
BANGE JOHANNES (DE)
KNYAZEV PJOTR (DE)
International Classes:
A61K38/17; A61K45/00; A61P35/00; A61P43/00; G01N33/50; C07K14/71; C07K16/28; C12N15/09; C12N15/12; C12Q1/68; G01N33/15; G01N33/566; A61K38/00; (IPC1-7): A61K31/40; C07K14/71; C07K16/28; C12N15/12; C12Q1/68
Download PDF: